- Home
- GMAB vs XPEV Comparison
GMAB vs XPEV Comparison
Compare GMAB & XPEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- XPEV
- Stock Information
- Founded
- GMAB 1999
- XPEV 2015
- Country
- GMAB Denmark
- XPEV China
- Employees
- GMAB N/A
- XPEV N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- XPEV Auto Manufacturing
- Sector
- GMAB Health Care
- XPEV Consumer Discretionary
- Exchange
- GMAB Nasdaq
- XPEV Nasdaq
- Market Cap
- GMAB 17.4B
- XPEV 21.7B
- IPO Year
- GMAB N/A
- XPEV 2020
- Fundamental
- Price
- GMAB $28.66
- XPEV $22.53
- Analyst Decision
- GMAB Strong Buy
- XPEV Buy
- Analyst Count
- GMAB 7
- XPEV 8
- Target Price
- GMAB $41.50
- XPEV $22.51
- AVG Volume (30 Days)
- GMAB 2.6M
- XPEV 8.9M
- Earning Date
- GMAB 11-06-2025
- XPEV 11-17-2025
- Dividend Yield
- GMAB N/A
- XPEV N/A
- EPS Growth
- GMAB 77.72
- XPEV N/A
- EPS
- GMAB 21.62
- XPEV N/A
- Revenue
- GMAB $3,646,881,232.00
- XPEV $8,416,181,216.00
- Revenue This Year
- GMAB $24.92
- XPEV $99.25
- Revenue Next Year
- GMAB $15.97
- XPEV $39.50
- P/E Ratio
- GMAB $1.33
- XPEV N/A
- Revenue Growth
- GMAB 32.97
- XPEV 66.37
- 52 Week Low
- GMAB $17.24
- XPEV $11.14
- 52 Week High
- GMAB $33.65
- XPEV $27.16
- Technical
- Relative Strength Index (RSI)
- GMAB 40.06
- XPEV 49.67
- Support Level
- GMAB $28.08
- XPEV $21.36
- Resistance Level
- GMAB $29.35
- XPEV $24.90
- Average True Range (ATR)
- GMAB 0.65
- XPEV 0.97
- MACD
- GMAB -0.27
- XPEV 0.02
- Stochastic Oscillator
- GMAB 25.93
- XPEV 36.20
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About XPEV XPeng Inc.
Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 190,000 EVs in 2024, accounting for about 2% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.